Irbesartan Zentiva

Irbesartan, the active ingredient in Irbesartan Zentiva, is a Angiotensin II receptor blocker (ARB) presented as an oral dosage form for oral use. It is employed to lower elevated blood pressure and to protect kidney function in patients with diabetic nephropathy.

GNH USA supplies Irbesartan Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to manage conditions linked to high blood pressure and kidney damage. - Hypertension: reduces systolic and diastolic blood pressure, lowering cardiovascular risk. - Diabetic nephropathy: slows progression of kidney disease in patients with type 2 diabetes. - Proteinuria in diabetes: decreases urinary protein excretion, indicating renal protection.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Angioedema: swelling of the face, lips, tongue, or throat that may impair breathing. - Hyperkalemia: elevated blood potassium levels that can affect heart rhythm. - Acute kidney injury: sudden decline in renal function requiring medical attention.

Before initiating therapy, consider the following safety measures. - Monitor blood pressure: ensure adequate control without excessive lowering. - Assess renal function: check serum creatinine and eGFR periodically. - Check serum potassium: avoid hyperkalemia, especially with potassium‑sparing agents. - Use caution in hepatic impairment: dose adjustments may be needed. - Avoid in patients with known hypersensitivity to irbesartan or other ARBs. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines; review patient medication lists carefully. Major Interactions (Avoid): - Aliskiren (in diabetes): combined use can increase renal risk. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors: concurrent use raises the chance of angioedema and kidney injury. Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, requiring dose titration. - NSAIDs: can diminish renal protective benefits and raise serum creatinine. - Lithium: irbesartan may increase lithium levels, necessitating close monitoring.